Is it safe to start fluconazole (Diflucan) in a patient who is currently taking nitrofurantoin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safety of Fluconazole (Diflucan) with Concurrent Nitrofurantoin Use

Yes, fluconazole can be started in a patient taking nitrofurantoin, but close monitoring for hepatotoxicity is essential given the potential for additive liver injury from both medications.

Key Safety Considerations

Hepatotoxicity Risk

  • Both nitrofurantoin and fluconazole independently carry risks of hepatotoxicity, making concurrent use a situation requiring heightened vigilance 1, 2.
  • Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities, primarily in patients with serious underlying medical conditions 1.
  • Nitrofurantoin can cause a broad spectrum of liver toxicity ranging from acute hepatitis to chronic active hepatitis that could lead to cirrhosis or death 2.

Documented Drug Interaction Case

  • A published case report documented combined pulmonary and hepatic toxicity when fluconazole was added to chronic nitrofurantoin therapy 3.
  • In this case, a 73-year-old man taking nitrofurantoin 50 mg daily for 5 years developed hepatic enzymes elevated 5 times the upper limit of normal within 2 months of starting fluconazole for onychomycosis 3.
  • The patient also developed pulmonary toxicity with dyspnea, pleuritic pain, and bilateral pulmonary disease on chest X-ray 3.
  • A potential drug interaction of unknown mechanism may have precipitated the nitrofurantoin-induced toxicity, though the exact pharmacokinetic mechanism remains unclear 3.

Clinical Management Algorithm

Before Starting Fluconazole

  • Obtain baseline liver function tests (AST, ALT, alkaline phosphatase, bilirubin) to establish a reference point 1.
  • Assess the patient's underlying medical conditions, as serious comorbidities increase hepatotoxicity risk 1.
  • Consider whether nitrofurantoin can be discontinued or if the urinary tract infection treatment course is nearly complete 3.

During Concurrent Therapy

  • Monitor liver function tests weekly during the first month of concurrent therapy, then every 2-4 weeks if treatment continues 1.
  • Instruct patients to report symptoms of liver injury immediately: fatigue, nausea, jaundice, dark urine, or right upper quadrant pain 1.
  • Discontinue both medications if clinical signs and symptoms consistent with liver disease develop 1.

Fluconazole Dosing Considerations

  • Standard fluconazole dosing for most Candida infections is 200 mg on day 1, followed by 100 mg once daily 1.
  • For vaginal candidiasis, a single 150 mg dose is appropriate 1.
  • Higher doses (up to 400 mg daily) may be used for systemic infections based on clinical response 1.

Important Caveats

Risk Factors for Hepatotoxicity

  • Advanced age, female sex, prolonged nitrofurantoin exposure, and reduced renal function increase hepatotoxicity risk 2.
  • The patient in the documented case report had been on chronic nitrofurantoin (5 years), which may have increased susceptibility 3.

Alternative Considerations

  • If the patient requires both medications and has risk factors for hepatotoxicity, consider alternative antifungal agents such as topical azoles for localized infections 4.
  • For systemic fungal infections requiring fluconazole, evaluate whether nitrofurantoin can be switched to an alternative antibiotic for the urinary tract infection 4.

Monitoring for Other Toxicities

  • While hepatotoxicity is the primary concern, be aware that nitrofurantoin can also cause pulmonary toxicity, which occurred in the documented interaction case 3.
  • Monitor for respiratory symptoms including dyspnea, cough, and pleuritic chest pain 3.

Bottom Line

The combination is not absolutely contraindicated, but requires careful risk-benefit assessment and close hepatic monitoring. The documented case of combined toxicity suggests a potential interaction mechanism, though fluconazole-drug interactions are generally frequent but have few apparent clinical consequences in most patients 5. Baseline and serial liver function tests are mandatory, and both drugs should be discontinued immediately if hepatotoxicity develops 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.